FCM
BPMC

Fieldview Capital Management’s Blueprint Medicines BPMC Stock Holding History

Fieldview Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,673
Closed -$599K – 402
2025
Q2 		$599K Sell
4,673
-22,757
-83% -$2.36M 0.09% 229
2025
Q1 		$2.43M Sell
27,430
-11,659
-30% -$1.14M 0.34% 112
2024
Q4 		$3.41M Buy
+39,089
New +$3.58M 0.53% 55

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Fieldview Capital Management's BPMC Position: Q3 2025 in Review

Fieldview Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,673 shares — an estimated $599K sold.

Fieldview Capital Management first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $3.41M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Fieldview Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Fieldview Capital Management sold 4,673 Blueprint Medicines shares in Q3 2025, an estimated $599K.
  • Fieldview Capital Management first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
  • Fieldview Capital Management's Blueprint Medicines position peaked at $3.41M in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Fieldview Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.